Gilead Sciences (GILD) Announces FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Gilead Sciences (GILD) Announces FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV

Gilead Sciences (GILD) PT Lowered to $76 at Barclays

April 29, 2024 5:23 AM EDT

Barclays analyst Carter Gould lowered the price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $80.00) while maintaining a Equalweight rating.

The analyst comments "'25 HIV zero-growth messaging, puts onus on cell therapy and seladelpar launch to deliver overall top-line growth. Focus... More